ClinicalTrials.gg
Not yet recruitingNCT07626359SEUpdated Sep 23, 2026

Randomized Non-inferiority Within-Patient Trial of Density Gradient Processing of Sequential Ejaculates Versus Centrifugation-free Sperm Separation Device for ICSI in Men With Elevated Sperm DNA Fragmentation.

An interventional study of Processed using density gradient centrifugation and Second Ejaculate (collected after 1-3 hours) in Male, sponsored by Indira IVF Hospital Pvt Ltd. Not yet recruiting at 9 sites in India. Open to participants aged 21 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Indira IVF Hospital Pvt Ltd · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
830
Allocation
Randomized
Ages
21 Years to 45 Years
Sex
All
01

Study summary

Elevated SDF can adversely impact fertilization, embryo development, and pregnancy outcomes in IVF-ICSI cycles. Two pragmatic strategies aim to reduce SDF on the day of ICSI: (i) obtaining a second ejaculate shortly after the first to reduce oxidative damage and transit time; and (ii) selecting sperm via centrifugation-free sperm separation device, which enriches for motile sperm with intact DNA. There are limited direct comparisons between these strategies; this study addresses that gap.

02

Conditions studied

  • Male

Keywords

  • pregnancy rate
  • Second Ejaculate
  • Abstinence
  • Microfluidic
  • CA0
03

In context

Lead sponsor

Indira IVF Hospital Pvt Ltd is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Elevated SDF defined as DFI >20 %measured by the sperm chromatin dispersion (SCD) test performed in a participating center's andrology laboratory, using a harmonized protocol under standardized conditions after 2-3 days of ejaculatory abstinence, and within 90 days (≤3 months) prior to enrollment.

      • Male partners 21-45 years;
      • Female partners 21-35 years.
      • Undergoing IVF/ICSI.
      • No known genetic or chromosomal abnormalities.
      • Minimum 4 MII oocyte patients shall be included

Exclusion criteria

Exclusion Criteria:

  • Azoospermia or severe oligoasthenozoospermia (\<1 million motile sperm/mL).
  • Significant systemic disease (e.g., uncontrolled diabetes, ).
  • History of a prior ICSI cycle with no embryo development.
  • Relevant female factors: untreated adnexal pathology ,a history of a thin endometrium (\<7 mm) following endometrium preparation for embryo transfer
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
830 participants (estimated)

Study arms

  • Experimental
    First Ejaculate

    Processed using a centrifugation-free sperm sorting device

    Procedure: Processed using density gradient centrifugation

  • Experimental
    Second Ejaculate

    The second ejaculate will be processed with two-layer density gradient centrifugation followed by standard washing.

    Procedure: Second Ejaculate (collected after 1-3 hours)

Interventions

  • ProcedureProcessed using density gradient centrifugation

    Processed using density gradient centrifugation

  • ProcedureSecond Ejaculate (collected after 1-3 hours)

    The second ejaculate will be processed with two-layer density gradient centrifugation followed by standard washing.

06

What researchers measure

Primary outcomes

  1. Ongoing Pregnancy Rate

    Ongoing pregnancy rate

    Time frame: 12 weeks of gestation

Secondary outcomes

  1. Sperm motility and morphology after sperm sorting or second ejaculate collection.

    Sperm motility and morphology after sperm sorting or second ejaculate collection.

    Time frame: At the day of ICSI

  2. Blastocyst rate

    Blastocyst rate

    Time frame: Day 5&6 after ICSI

  3. Good Blastocyst rate

    Total number of good blast

    Time frame: Day 5&6 after ICSI

  4. Biochemical Pregnancy Rate

    Biochemical Pregnancy Rate

    Time frame: 2 weeks after embryo transfer

  5. Implantation Rate

    An embryo implantation rate is the percentage of transferred embryos that successfully attach to the uterine lining and develop into a clinical pregnancy

    Time frame: 4-6 weeks after embryo transfer

  6. Clinical Pregnancy Rate

    measures the percentage of fertility treatment cycles (like IVF) that result in a pregnancy confirmed by an ultrasound showing a gestational sac or fetal heartbeat

    Time frame: 4-6 weeks after embryo transfer

  7. First trimester Miscarriage Rate

    Miscarriages are very common, occurring in about 10% to 20% of all known pregnancies.

    Time frame: Till 12 weeks after embryo transfer

07

Study locations

9 sites
08

References and documents

Publications

  • Humaidan P, Haahr T, Povlsen BB, Kofod L, Laursen RJ, Alsbjerg B, Elbaek HO, Esteves SC. The combined effect of lifestyle intervention and antioxidant therapy on sperm DNA fragmentation and seminal oxidative stress in IVF patients: a pilot study. Int Braz J Urol. 2022 Jan-Feb;48(1):131-156. doi: 10.1590/S1677-5538.IBJU.2021.0604. PubMed 34472769 ↗
  • https://www.sciencedirect.com/science/article/pii/S0015028215018749

Individual participant data

Plan to share: No — Data will be shared on request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2026
First posted
Jun 4, 2026
StartEst.
Oct 5, 2026
Primary completionEst.
Dec 25, 2027
CompletionEst.
Mar 25, 2028
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07626359
Lead sponsor
Indira IVF Hospital Pvt Ltd
Responsible party
Dr Vipin Chandra (Chief Clinical and Lab Operations, Indira IVF Hospital Pvt Ltd) — Principal investigator
First posted
Jun 4, 2026
Start date
Oct 5, 2026 (estimated)
Primary completion
Dec 25, 2027 (estimated)
Completion
Mar 25, 2028 (estimated)
Last update
Sep 23, 2026

Study contacts

Shashank Sanagoudar, MS
Contact
drsanagoudar@gmail.com
91-8050406053
Sandro Esteves, PhD
Contact
s.esteves@androfert.com.br
Vipin Chandra, DGO
principal investigator · Indira IVF Hospital Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion